GREY:IPHAF - Post by User
Post by
claritason Jul 02, 2008 8:30am
743 Views
Post# 15248901
RBC drops target to $3 from $4
RBC drops target to $3 from $4RBC has lowered price due to launch timeline moved back one year.
Analyst also goes into pros and cons for Roche:
- surveyed physicians who would switch to voclosporin for safety reasons versus efficacy
-becomes a question of
- marketing : tacrolimus in generic form could make things difficult,
- competition in development of alternatives
Not a slam dunk. Non-inferior does not translate into across-the-board superiority
Conclusion from RBC - 'Roche decision may be too tough to call'.
Unless Roche opts in, the PhaseIII trials may take a long time and provide limited news ahead.
Thus the share price reflects this situation and the stock, in my view, remains a very very speculative stock.